A
Anne-Marie C. Dingemans
Researcher at Maastricht University
Publications - 282
Citations - 10416
Anne-Marie C. Dingemans is an academic researcher from Maastricht University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 49, co-authored 219 publications receiving 8346 citations. Previous affiliations of Anne-Marie C. Dingemans include Erasmus University Rotterdam & Maastricht University Medical Centre.
Papers
More filters
Journal ArticleDOI
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang,Suresh Senan,Marinus A. Paul,Reza J. Mehran,Alexander V. Louie,Peter A Balter,Harry J.M. Groen,Stephen E. McRae,Joachim Widder,Lei Feng,Ben E. E. M. van den Borne,Mark F. Munsell,Coen W. Hurkmans,Donald A. Berry,Erik van Werkhoven,John J. Kresl,Anne-Marie C. Dingemans,Omar Dawood,Cornelis J.A. Haasbeek,Larry S. Carpenter,Katrien De Jaeger,Ritsuko Komaki,Ben J. Slotman,Egbert F. Smit,Jack A. Roth +24 more
TL;DR: Overall survival for SABR versus surgery by pooling data from the STARS and ROSEL trials was 95% (95% CI 85-100) in the S ABR group compared with 79% in the surgery group, and recurrence-free survival at 3 years was 86% ( 95% CI 74-100).
Journal ArticleDOI
Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation.
Annemie M. W. J. Schols,Peter B. Soeters,Anne-Marie C. Dingemans,R. Mostert,Peter J. Frantzen,Emiel F.M. Wouters +5 more
TL;DR: It is concluded that fat-free mass is a better indicator of body mass depletion than body weight.
Journal ArticleDOI
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
Julien Mazieres,Gérard Zalcman,L. Crinò,Pamela Biondani,Fabrice Barlesi,Thomas Filleron,Anne-Marie C. Dingemans,Hervé Lena,Isabelle Monnet,Sacha I. Rothschild,Federico Cappuzzo,Benjamin Besse,Luc Thiberville,Damien Rouviere,Rafal Dziadziuszko,Egbert F. Smit,Jürgen Wolf,Christian Spirig,Nicolas Pécuchet,Frauke Leenders,Johannes M. Heuckmann,Joachim Diebold,Julie Milia,Roman K. Thomas,Oliver Gautschi +24 more
TL;DR: Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1.
Journal ArticleDOI
Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450)
Dirk De Ruysscher,Rinus Wanders,Angela van Baardwijk,Anne-Marie C. Dingemans,Bart Reymen,Ruud Houben,Gerben Bootsma,Cordula Pitz,Linda van Eijsden,Wiel Geraedts,Brigitta G. Baumert,Philippe Lambin +11 more
TL;DR: Long-term PFS was found in a subgroup of NSCLC patients with synchronous oligometastases when treated radically, and identification of this favorable subgroup before therapy is needed is needed.
Journal ArticleDOI
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan
Hugo J.W.L. Aerts,Angela van Baardwijk,Steven F. Petit,C. Offermann,Judith van Loon,Ruud Houben,Anne-Marie C. Dingemans,Rinus Wanders,Liesbeth J. Boersma,Jacques Borger,Gerben Bootsma,Wiel Geraedts,Cordula Pitz,Jean Simons,Bradly G. Wouters,M Oellers,Philippe Lambin,Geert Bosmans,Andre Dekker,Dirk De Ruysscher +19 more
TL;DR: The location of residual metabolic-active areas within the primary tumour after therapy corresponded with the original high FDG uptake areas pre-radiotherapy, ultimately enabling selective-boosting of tumour sub-volumes.